Part

Engine Components Market Value to reach US$ 8.1 billion by 2031, Transparency Market Research, Inc.

Retrieved on: 
Monday, January 23, 2023
Beryllium, Automation, Mining, Vehicle, Employment, Alloy, Transport, US, Growth, Urbanization, Part, Car, Research

The global market is anticipated to expand at a CAGR of 1.4% during the forecast period from 2022 to 2031.

Key Points: 
  • The global market is anticipated to expand at a CAGR of 1.4% during the forecast period from 2022 to 2031.
  • Thus, rise in demand for off-highway engines is anticipated to drive the global engine components market.
  • Leading players are investing in enhancing performance of engine systems and engine components owing to strict regulations concerning vehicle emissions enforced by regulatory agencies.
  • As per market research on engine components, the market in Asia Pacific is expected to dominate the global industry.

EnerCom Announces The Energy Venture Investment Summit 2023 will now be part of the EnerCom Dallas Investor Conference April 18 -19, 2023 at Hotel Crescent Court, Downtown Dallas

Retrieved on: 
Thursday, January 19, 2023
Summit, Lunch, Oil, Conference, Studio X, Q&A, News, Energy, Colorado School of Mines, Innospec, Closing Bell, Business Energy Investment Tax Credit, ESG, ARC Centre of Excellence in Future Low-Energy Electronics Technologies, Breakfast, Bell, Location, Carbon, Part, Science, Engineering, Renewable energy, Pharmaceutical industry, Security (finance), Cryptocurrency, Music, Financial services

DENVER, Jan. 19, 2023 /PRNewswire/ -- EnerCom, Inc., a nationally-recognized management consultancy firm, announced today that it will now be hosting the annual The Energy Venture Investment Summit 2023 as part of the EnerCom Dallas Investor Conference, April 18 -19, 2023 at Hotel Crescent Court, Downtown Dallas.

Key Points: 
  • DENVER, Jan. 19, 2023 /PRNewswire/ -- EnerCom, Inc., a nationally-recognized management consultancy firm, announced today that it will now be hosting the annual The Energy Venture Investment Summit 2023 as part of the EnerCom Dallas Investor Conference, April 18 -19, 2023 at Hotel Crescent Court, Downtown Dallas.
  • There is no cost to attend EnerCom Dallas and The Energy Venture Investment Summit for qualified investors.
  • Investors can now register to attend the Summit as part of EnerCom Dallas – The Energy Investment and ESG Conference at www.enercomdallas.com .
  • In addition to The Energy Venture Investment Summit and EnerCom Dallas , EnerCom will be hosting the 28th annual EnerCom Denver energy investment conference on August 13-16, 2023.

21 CFR Part 11, SaaS/Cloud, EU GDPR Course: Reduce Costs for Compliance with Data Integrity (February 1-2, 2023)

Retrieved on: 
Thursday, January 19, 2023
Cloud, Verification and validation, FDA, Clinical trial, Software as a service, Title 21 CFR Part 11, GxP, Software, Computer, Part, Medical device, EU

DUBLIN, Jan. 19, 2023 /PRNewswire/ -- The "Reduce costs for compliance with data integrity: 21 CFR Part 11, SaaS/Cloud, EU GDPR" training has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Jan. 19, 2023 /PRNewswire/ -- The "Reduce costs for compliance with data integrity: 21 CFR Part 11, SaaS/Cloud, EU GDPR" training has been added to ResearchAndMarkets.com's offering.
  • It details the requirements for Part 11 and Annex 11: SOPs, software product features, infrastructure qualification, and validation.
  • The instructor addresses the latest computer system industry standards for data security, data transfer, audit trails, electronic records and signatures, software validation, and computer system validation.
  • Participants learn how to decrease software implementation times and lower costs using a 10-step risk-based approach to computer system validation.

EQS-News: Immunic to Host Virtual Celiac Disease R&D Day to Highlight Current Pathways for Drug Development and Unmet Medical Need

Retrieved on: 
Monday, February 13, 2023
ET, Hepatology, Conference call, Conference, Internal medicine, DRS, Coeliac disease, Degenerative disease, Therapy, Mayo Clinic, Patient, Clinical trial, Disease, Division, Part, Research, Management, Dentistry, Pharmaceutical industry, Rheumatology, Webcast, Short course immune induction therapy, Gastroenterology

“We look forward to hosting this deep-dive discussion, focused on the current challenges of treating celiac disease with two, such renowned thought leaders as Drs.

Key Points: 
  • “We look forward to hosting this deep-dive discussion, focused on the current challenges of treating celiac disease with two, such renowned thought leaders as Drs.
  • Murray and Schumann,” stated Daniel Vitt, Ph.D., Chief Executive Officer and President of Immunic.
  • Registrants will receive a confirmation email containing a link for online participation or a telephone number for dial in access.
  • An archived replay of the webcast will be available approximately one hour after completion on Immunic’s website at: ir.imux.com/events-and-presentations .

Advertisers should be uneasy about unproven disease claims

Retrieved on: 
Monday, February 13, 2023
Transfer, Online, Comment, FTC, Hypertension, TSR, Dementia, Judgement, Federal Trade Commission Act of 1914, Complaint, Fraud, Part, Arthralgia, Food, Stethoscope, Trial of the century, Privacy, Federal Trade Commission, Policy, Attention, Electronic Fund Transfer Act, Brain, Blog, Diabetes, Arthritis, LLC, Record, Exercise, Disease, Amnesia, Depression, ROSCA, Science, Public, Dietary supplement, Online shopping, Sales
Key Points: 

Ayala Pharmaceuticals Reports Financial Results For the Fiscal Year Ended October 31, 2022

Retrieved on: 
Friday, February 10, 2023
Research, Prostate cancer, Safety, ACC, G&A, Plantar fibromatosis, Fast Track, ESMO, Security (finance), Annual report, PSA, Survival, Poster, Adenoid cystic carcinoma, Patient, ASCO, Form 10-K, FDA, Part, PFS, Columbia University, Advaxis, Pharmaceutical industry, Airline

REHOVOT, Israel and MONMOUTH JUNCTION, N.J., Feb. 10, 2023 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (f/k/a Advaxis Inc.) (the “Company,” “New Ayala,” “we,” “us” or “our”) (OTCQX: ADXS), a clinical-stage oncology company, today announces financial results for the fiscal year ended October 31, 2022.

Key Points: 
  • REHOVOT, Israel and MONMOUTH JUNCTION, N.J., Feb. 10, 2023 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (f/k/a Advaxis Inc.) (the “Company,” “New Ayala,” “we,” “us” or “our”) (OTCQX: ADXS), a clinical-stage oncology company, today announces financial results for the fiscal year ended October 31, 2022.
  • New Ayala’s Consolidated Financial Results for the Fiscal Year Ended October 31, 2022
    Cash position On October 31, 2022, the consolidated cash and cash equivalents position was $25.2 million.
  • R&D expenses: Research and development expenses for fiscal year 2022 were $7.6 million, compared with $10.6 million for fiscal year 2021.
  • Old Ayala will report consolidated financial results for the full year ended December 31, 2022 (a period completed prior to the merger) on or about March 31, 2023.

Mesa Airlines Launches Direct-Entry Captain Position to United Airlines

Retrieved on: 
Tuesday, February 7, 2023
Part, FAA, MESA, Aircraft pilot, Direct-entry midwife, Aircraft, Mesa, Mesa Airlines, Airline, Real estate, United, United Airlines

PHOENIX, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Mesa Airlines, Inc (NASDAQ: MESA) is launching a Direct-Entry Captain Position for highly qualified candidates with a 24-month flow to United Airlines.

Key Points: 
  • PHOENIX, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Mesa Airlines, Inc (NASDAQ: MESA) is launching a Direct-Entry Captain Position for highly qualified candidates with a 24-month flow to United Airlines.
  • With the launch of the Direct-Entry Captain Position to United, Mesa will offer highly qualified candidates the most competitive overall package in terms of compensation and career opportunity, including:
    $110,000 sign-on bonus paid in full at completion of training.
  • Earning potential between $150 to $215 a flight hour as a Captain at Mesa before transitioning to United.
  • United is the fastest growing, best positioned and most employee friendly airline in America.”
    Candidates for Direct-Entry Captain have immediate class dates available without training delays.

Lyra Therapeutics Announces Completion of Enrollment in the BEACON Phase 2 Clinical Trial of LYR-220 in Post-Surgical Chronic Rhinosinusitis Patients

Retrieved on: 
Monday, February 6, 2023
Safety, LYRA, MF, Sinusitis, Mometasone, Patient, Clinical trial, CRS, Part, Therapy, Pharmaceutical industry, Lyra

WATERTOWN, Mass., Feb. 06, 2023 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (the Company or Lyra), a clinical-stage biotechnology company developing innovative therapies for the localized treatment of chronic rhinosinusitis (CRS), today announced completion of enrollment in the Phase 2 BEACON clinical trial of LYR-220 in adult patients with CRS who have had prior sinus surgery. LYR-220 is designed to deliver six months of continuous anti-inflammatory medication (mometasone furoate; MF) to the sinonasal passages for the treatment of CRS. Topline results are expected in the fourth quarter of 2023.

Key Points: 
  • LYR-220 is designed to deliver six months of continuous anti-inflammatory medication (mometasone furoate; MF) to the sinonasal passages for the treatment of CRS.
  • “Our momentum with the LYR-220 program in post-surgical CRS patients adds to our continued progress with LYR-210, which is in pivotal Phase 3 trials for surgically-naïve CRS patients.
  • In September 2022, Lyra announced positive initial data from the Part 1, non-randomized portion of the BEACON trial, demonstrating the feasibility and tolerability of LYR-220 placement bilaterally in this patient population.
  • All six patients were treated for at least six weeks and no serious or unexpected product-related adverse events were reported.

Turmalina Announces Up-Sizing of Financing to $5,000,000 and Closes Book

Retrieved on: 
Monday, February 6, 2023
TSX Venture Exchange, National instrument, Unit, Offering, Sale, Person, NOT, Part, FOR, News, Bank, Security (finance)

VANCOUVER, British Columbia, Feb. 06, 2023 (GLOBE NEWSWIRE) -- Turmalina Metals Corp. (“Turmalina”, or the “Company”; TBX-TSXV, TBXXF-OTCQX, 3RI-FSE) is pleased to announce that it is increasing the maximum number of units of the Company (the “Units”) in connection with its previously disclosed non-brokered private placement (the “Offering”) to 11,111,111 Units at a price of $0.45 per Unit for aggregate gross proceeds of up to $5,000,000. All other terms of the Offering remain the same.

Key Points: 
  • All other terms of the Offering remain the same.
  • The closing of the Offering remains subject to standard conditions, including acceptance of subscriptions by the Company, approval of the TSX Venture Exchange, and receipt of all funds.
  • There is an offering document related to the Offering that will be available under the Company’s profile at www.sedar.com and at https://turmalinametals.com/.
  • Address: #488 - 1090 West Georgia St, Vancouver, BC V6E 3V7.

Addex Strategic Partner Completes Enrollment in ADX71149 Epilepsy Phase 2 Study Part 1

Retrieved on: 
Monday, February 6, 2023
Janssen Pharmaceuticals, PAM, Seizure, Levetiracetam, Part 1, Safety, Patient, LR, SIX, Pharmacokinetics, IRC, Metcalf, Therapy, Glutamic acid, Janssen, Part, ADX71149, Johnson & Johnson, Maintenance, Brain, Pharmaceutical industry, Epilepsy

53 LR

Key Points: 
  • 53 LR
    Geneva, Switzerland, February 6, 2023 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced that enrollment into Part 1 of the Phase 2 clinical study of ADX71149 (JNJ-40411813) for the treatment of epilepsy has been completed.
  • Data from Part 1 will now be evaluated by an independent interim review committee (IRC) to ensure the study remains blinded.
  • “The Phase 2 study evaluating ADX71149 in epilepsy continues to make progress and we are pleased our collaboration partner has completed enrollment into Part 1 of the study,” said Tim Dyer, CEO of Addex.
  • The primary objective of the study is to evaluate the efficacy of ADX71149 in combination with levetiracetam using a time to seizure event endpoint.